Lexology July 21, 2025
Four U.S. senators reported their findings of a nine-month investigation into direct-to-consumer telehealth platforms used by pharmaceutical manufacturers, highlighting risks and reinforcing the need for industry to carefully consider the regulatory requirements and emerging enforcement scrutiny of such arrangements, particularly under the federal Anti-Kickback Statue (AKS).
We discussed pharmaceutical telehealth arrangements in our Horizons 2025 life sciences and health care edition and predicted they may come under increased scrutiny.
The investigation by Senators Dick Durbin, Bernie Sanders, Elizabeth Warren, and Peter Welch focused on two major pharmaceutical manufacturers, their telehealth platforms, and the telehealth providers to which those platforms linked. It comes in the wake of the U.S. Department of Health and Human Services Office of Inspector General’s (OIG’s) 2022...
Today's Sponsors
Today's Sponsor